Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 1158-1162

  Marks, D I ^a   Kurz, B W ^a   Link, M P ^a   Ng, E ^a   Shuster, J J ^a   Lauer, S J ^a   Carroll, D ^a   Brodsky, I ^a   Haines, D S ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0031059357     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.1158     Document Type: Article

References (24)

1. Rivera GA, Crist WM: Acute lymphoblastic leukemia, in Handin RI, Lux SE, Stossel TP (eds): Blood. Principles and Practice of Hematology. Philadelphia, PA, Lippincott, 1995, pp 743-782
2. Pui C-H: Childhood leukemias. N Engl J Med 332:1618-1630, 1995
3. Crist WM, Carroll A, Shuster J, et al: Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13). Blood 76:117-122, 1990
4. Fletcher JA, Lynch EA, Kimball VM, et al: Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lypmphoblastic leukemia. Blood 77:435-439, 1991
5. Heyman M, Rasool O, Borgonovo Brandter L, et al: Prognostic importance of p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic leukemia. J Clin Oncol 14:1512-1520, 1996
6. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancer. J Natl Cancer Inst 84:845-855, 1992
7. Martin HM, Filipe MI, Morris RW, et al: p53 expression and prognosis in gastric carcinoma. Int J Cancer 50:859-862, 1992
8. Horio Y, Takahashi T, Hibi K, et al: Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53:1-4, 1993
9. Wattel E, Preudhomme C, Hecquet B, et al: p53 mutations are associated with resistance to chemotherapy and short survival in hematological malignancies. Blood 84:3148-3157, 1994
10. Wada M, Bartram CR, Nakamura H, et al: Analysis of p53 mutations in a large series of lymphoid malignancies of childhood. Blood 82:3163-3169, 1993
11. Momand J, Zambetti GP, Olson D, et al: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245, 1992
12. Oliner JD, Pietenpol JA, Thiagalingam S, et al: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860, 1993
13. Finlay CA: The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13:301-306, 1993
14. 1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16:2445-2452, 1996
15. Mahoney DH, Camitta BM, Leventhal BG, et al: Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. Cancer 75:2623-2631, 1995
16. Lauer SJ, Toledano S, Winich N, et al: A comparison of early intensive methotrexate/mercaptopurine (MTX/MP) vs early intensive alternating chemotherapy for high risk acute lymphoblastic leukemia (HR-ALL): A Pediatric Oncology Group (POG) randomized phase III study. Proc Am Soc Clin Oncol 14:342, 1995 (abstr)
17. Marks DI, Kurz BW, Link MP, et al: High incidence of potential p53 pathway inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 87:1155-1161, 1996
18. Landers JE, Haines DS, Strauss JF III, et al: Enhanced translation: A novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9:2745-2750, 1994
19. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70:523-526, 1992
20. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991
21. Villuendas R, Piris MA, Algara P, et al: The expression of p53 protein in non-Hodgkin's lymphoma is not always dependent on p53 gene mutations. Blood 82:3151-3156, 1993
22. Bueso-Ramos CE, Yang Y, deLeon E, et al: The human MDM-2 oncogene is overexpressed in leukemias. Blood 82:2617-2623, 1993
23. Zhou M, Yeager AM, Smith SD, et al: Overexpression of the mdm2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 85:1608-1614, 1995
24. Diccianni MB, Yu J, Hsiao M, et al: Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 84:3105-3112, 1994